Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
LVTX 
LAVA Therapeutics NV (LVTX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: LVTX (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $1.38
1 Year Target Price $1.38
| 1 | Strong Buy |
| 0 | Buy |
| 3 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 15.8% | Avg. Invested days 47 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 40.77M USD | Price to earnings Ratio - | 1Y Target Price 1.38 |
Price to earnings Ratio - | 1Y Target Price 1.38 | ||
Volume (30-day avg) 4 | Beta 0.49 | 52 Weeks Range 0.85 - 2.09 | Updated Date 08/29/2025 |
52 Weeks Range 0.85 - 2.09 | Updated Date 08/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.06 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Earnings Date
Report Date 2025-08-13 | When - | Estimate -0.3 | Actual -0.32 |
Profitability
Profit Margin - | Operating Margin (TTM) -521.84% |
Management Effectiveness
Return on Assets (TTM) -21.3% | Return on Equity (TTM) -90.19% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -15395793 | Price to Sales(TTM) 8.17 |
Enterprise Value -15395793 | Price to Sales(TTM) 8.17 | ||
Enterprise Value to Revenue 2.12 | Enterprise Value to EBITDA 0.81 | Shares Outstanding 26305300 | Shares Floating 10221975 |
Shares Outstanding 26305300 | Shares Floating 10221975 | ||
Percent Insiders 32.69 | Percent Institutions 36.39 |
Upturn AI SWOT
LAVA Therapeutics NV
Company Overview
History and Background
LAVA Therapeutics N.V. is a biotechnology company focused on developing bispecific gamma-delta T cell engagers for cancer. Founded in 2017, the company leverages its Gammabody platform to create therapies that activate gamma-delta T cells to kill cancer cells. It is headquartered in Utrecht, Netherlands.
Core Business Areas
- Immuno-Oncology: Development of novel immunotherapies targeting gamma-delta T cells to treat various cancers.
Leadership and Structure
The leadership team consists of experienced biotech executives and scientists. The company operates with a structure typical of a clinical-stage biotechnology company, with research, development, clinical, and administrative functions.
Top Products and Market Share
Key Offerings
- LAVA-051: A bispecific gamma-delta T cell engager targeting EGFR on cancer cells and Vu03b39Vu03b42 T cells. Currently in Phase 1/2a clinical trials for solid tumors. Competitors include companies developing similar T cell engagers and EGFR-targeted therapies. Market share data is not yet available due to its developmental stage.
- LAVA-1207: A bispecific gamma-delta T cell engager targeting PSMA on cancer cells and Vu03b39Vu03b42 T cells. Currently in Phase 1/2a clinical trials for metastatic castration-resistant prostate cancer (mCRPC). Competitors include companies developing PSMA-targeted therapies and other immunotherapies for prostate cancer. Market share data is not yet available due to its developmental stage.
Market Dynamics
Industry Overview
The immuno-oncology market is rapidly growing, with increasing demand for novel cancer therapies. The bispecific antibody market, in particular, is experiencing significant growth.
Positioning
LAVA Therapeutics is positioned as an innovator in the gamma-delta T cell engager space, targeting difficult-to-treat cancers.
Total Addressable Market (TAM)
The TAM for immuno-oncology is estimated to be in the hundreds of billions of dollars. LAVA is focusing on niche areas within this TAM, specifically cancers addressable by gamma-delta T cell engagers.
Upturn SWOT Analysis
Strengths
- Novel Gammabody platform
- Focus on gamma-delta T cells
- Experienced management team
- Pipeline of bispecific antibodies
Weaknesses
- Clinical-stage company with no approved products
- High cash burn rate
- Dependence on clinical trial success
- Limited market validation
Opportunities
- Positive clinical trial results
- Partnerships with larger pharmaceutical companies
- Expansion into new cancer indications
- Advancements in gamma-delta T cell biology
Threats
- Clinical trial failures
- Competition from established immuno-oncology therapies
- Regulatory hurdles
- Economic downturn affecting funding
Competitors and Market Share
Key Competitors
- XOMA (XOMA)
- MacroGenics (MGNX)
- Amgen (AMGN)
Competitive Landscape
LAVA Therapeutics is competing with established immuno-oncology players and companies developing bispecific antibodies. Its gamma-delta T cell engager approach is a differentiator but carries inherent risks.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by advancement of the pipeline and establishment of clinical programs.
Future Projections: Future growth depends on the success of clinical trials and potential partnerships.
Recent Initiatives: Advancing LAVA-051 and LAVA-1207 into later-stage clinical trials, exploring new target opportunities using the Gammabody platform.
Summary
LAVA Therapeutics is a clinical-stage biotechnology company with an innovative Gammabody platform targeting gamma-delta T cells for cancer immunotherapy. Its strengths lie in its novel technology and experienced team, while weaknesses include its early-stage status and high cash burn. Positive clinical trial results and strategic partnerships could drive future growth, but clinical trial failures and competition pose significant threats. Overall, it's a high-risk, high-reward investment.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports
- ClinicalTrials.gov
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Investment decisions should be made based on thorough research and consultation with a financial advisor. Market share data is estimated and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About LAVA Therapeutics NV
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2021-03-25 | CEO, President & Executive Director Mr. Stephen Allen Hurly M.B.A., M.Sc. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 34 | Website https://www.lavatherapeutics.com |
Full time employees 34 | Website https://www.lavatherapeutics.com | ||
LAVA Therapeutics N.V. operates as a clinical-stage immuno-oncology company that focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. Its lead clinical-stage candidates are LAVA-1207 that is in Phase 1/2a clinical trial for metastatic castration-resistant prostate cancer. The company is developing other Gammabody drug candidates, which include LAVA-1223, which targets the epidermal growth factor receptor (EGFR) for the treatment of selected solid tumors, as well as LAVA-1266 which are preclinical candidates for the treatment of various hematologic malignancies. The company has a research collaboration and license agreement with Janssen Biotech, Inc. for the potential discovery and development of multi-specific antibody products that are directed to a specified target in various fields of use; and a collaboration with Merck & Co., Inc. to evaluate anti-PD-1 therapy KEYTRUDA in combination with LAVA-1207. LAVA Therapeutics N.V. was incorporated in 2016 and is based in Utrecht, the Netherlands.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.